+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID06933914

Open-label Study to Assess Long-term Safety and Tolerability of MY008211A Tablets in Adults with Paroxysmal Nocturnal Hemoglobinuria

Led by Wuhan Createrna Science and Technology Co., Ltd · Updated on 2025-04-18

120

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the long-term safety, tolerability, and effectiveness of MY008211A tablets in patients with Paroxysmal Nocturnal Hemoglobinuria PNH. It provides continued access to MY008211A for patients who have previously completed Phase 2 or Phase 3 trials of the drug and have derived benefit from it. This open-label, single-arm, multicenter study focuses on understanding the ongoing impact of MY008211A treatment in this patient group. Participants in this study will take MY008211A tablets at a dose of 400 mg twice daily. The study allows patients who completed earlier trials without tapering down their treatment to continue receiving MY008211A. This single treatment group design means all participants receive the study drug openly without a placebo or comparator. During the study, participants will be monitored for adverse events, laboratory safety parameters, vital signs, and ECG over about 100 weeks. Researchers will assess outcomes such as sustained hemoglobin levels without transfusions, changes in hemoglobin from baseline, rates of red blood cell transfusion avoidance, clinical breakthrough hemolysis, and major adverse vascular events. The study provides long-term safety and efficacy information while ensuring ongoing treatment access for eligible patients.

CONDITIONS

Brief Title

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Research Team

W

Wuhan Createrna Science and Technology Co.,Ltd

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here